MX387020B - Fluido terapeutico peritoneal. - Google Patents

Fluido terapeutico peritoneal.

Info

Publication number
MX387020B
MX387020B MX2018000336A MX2018000336A MX387020B MX 387020 B MX387020 B MX 387020B MX 2018000336 A MX2018000336 A MX 2018000336A MX 2018000336 A MX2018000336 A MX 2018000336A MX 387020 B MX387020 B MX 387020B
Authority
MX
Mexico
Prior art keywords
therapeutic fluid
peritoneal therapeutic
polyphenolic compound
peritoneal
bca
Prior art date
Application number
MX2018000336A
Other languages
English (en)
Spanish (es)
Other versions
MX2018000336A (es
Inventor
Guido Grentzmann
Original Assignee
Opterion Health Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opterion Health Ag filed Critical Opterion Health Ag
Publication of MX2018000336A publication Critical patent/MX2018000336A/es
Publication of MX387020B publication Critical patent/MX387020B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
MX2018000336A 2015-07-20 2016-07-19 Fluido terapeutico peritoneal. MX387020B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Publications (2)

Publication Number Publication Date
MX2018000336A MX2018000336A (es) 2018-05-22
MX387020B true MX387020B (es) 2025-03-19

Family

ID=53785450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000336A MX387020B (es) 2015-07-20 2016-07-19 Fluido terapeutico peritoneal.

Country Status (23)

Country Link
US (2) US20180221303A1 (enExample)
EP (2) EP3120842A1 (enExample)
JP (1) JP6448847B2 (enExample)
KR (2) KR102266889B1 (enExample)
CN (2) CN110075307A (enExample)
AU (1) AU2016296216B2 (enExample)
BR (1) BR112018001005B1 (enExample)
CA (1) CA2990532C (enExample)
CO (1) CO2018000236A2 (enExample)
CY (1) CY1124467T1 (enExample)
DK (1) DK3324951T3 (enExample)
ES (1) ES2880796T3 (enExample)
HR (1) HRP20211319T1 (enExample)
HU (1) HUE055208T2 (enExample)
LT (1) LT3324951T (enExample)
MX (1) MX387020B (enExample)
PL (1) PL3324951T3 (enExample)
PT (1) PT3324951T (enExample)
RS (1) RS62142B1 (enExample)
RU (1) RU2718908C2 (enExample)
SI (1) SI3324951T1 (enExample)
SM (1) SMT202100428T1 (enExample)
WO (1) WO2017013120A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
WO2020081654A1 (en) * 2018-10-16 2020-04-23 President And Fellows Of Harvard College Sirt1 activating compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
IL147500A0 (en) * 1999-08-10 2002-08-14 Ml Lab Plc Method for delivery of therapeutic agents using a solution of dextrin
AU7879500A (en) 1999-10-15 2001-04-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
CN101296693B (zh) 2005-10-26 2012-07-04 花王株式会社 持久力提高剂
ES2685094T3 (es) * 2007-07-31 2018-10-05 Elc Management Llc Composiciones cosméticas que contienen resveratrol
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
KR20110096132A (ko) * 2008-11-26 2011-08-29 리포프로틴 테크놀로지스, 인코포레이티드 레스베라트롤의 향상된 생활성 제제
EP3085365A3 (en) * 2009-01-19 2017-01-04 Lycored Ltd. Synergistic combinations of carotenoids and polyphenols
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
PE20150288A1 (es) * 2012-04-24 2015-02-22 Univ British Columbia Dialisato a base de polimero
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
ITRM20130135A1 (it) * 2013-03-06 2014-09-07 Michele Azzolini Nuovi derivati del resveratrolo.
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Also Published As

Publication number Publication date
BR112018001005A2 (pt) 2022-09-06
CY1124467T1 (el) 2022-07-22
RU2018106122A3 (enExample) 2019-10-10
US11160766B2 (en) 2021-11-02
BR112018001005B1 (pt) 2023-11-28
ES2880796T3 (es) 2021-11-25
PL3324951T3 (pl) 2021-12-13
HUE055208T2 (hu) 2021-11-29
MX2018000336A (es) 2018-05-22
SMT202100428T1 (it) 2021-09-14
US20180221303A1 (en) 2018-08-09
EP3324951B1 (en) 2021-05-26
PT3324951T (pt) 2021-07-20
CN107921009A (zh) 2018-04-17
LT3324951T (lt) 2021-07-26
SI3324951T1 (sl) 2021-09-30
CA2990532A1 (en) 2017-01-26
US20200022926A1 (en) 2020-01-23
RS62142B1 (sr) 2021-08-31
WO2017013120A1 (en) 2017-01-26
AU2016296216A1 (en) 2017-12-14
HK1251176A1 (zh) 2019-01-25
DK3324951T3 (da) 2021-08-23
CN110075307A (zh) 2019-08-02
CO2018000236A2 (es) 2018-06-12
CA2990532C (en) 2020-07-14
EP3324951A1 (en) 2018-05-30
KR102266889B1 (ko) 2021-06-18
CN107921009B (zh) 2020-12-11
EP3120842A1 (en) 2017-01-25
RU2018106122A (ru) 2019-08-20
HRP20211319T1 (hr) 2021-11-26
RU2718908C2 (ru) 2020-04-15
JP6448847B2 (ja) 2019-01-09
JP2018522894A (ja) 2018-08-16
KR20180048577A (ko) 2018-05-10
KR20190025759A (ko) 2019-03-11
AU2016296216B2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
CL2015002708A1 (es) Compuestos heterocíclicos y sus usos.
IL280360A (en) Aortic cannula for ex vivo organ care system
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
MX369921B (es) Tratamiento de la hgna y ehna.
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2017016096A (es) Agente antihipertensivo.
CY1124467T1 (el) Περιτοναϊκο θεραπευτικο υγρο
MX2017002737A (es) Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
MX381598B (es) Combinación farmacéutica que comprende un parvovirus y bevacizumab.
MX2018014915A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
EP3394038A4 (en) TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH SPECIFIC CORTISTATINE DERIVATIVES
MX376087B (es) Inhibidores macrocíclicos de cinasa rip2.
MX374165B (es) Aducto de ciclodextrina-panobinostat
MX2018003802A (es) Formulacion de hipericina para el diagnostico fotodinamico.
CO2018011200A2 (es) Marcador para predecir la respuesta al tratamiento del agente anticancerígeno en pacientes con cáncer
BR112018011367A2 (pt) composição de fluidos para tratamento de poços
MX2016011310A (es) Agente para el control de endoparasitos.
MX2019007490A (es) Composicion que contiene acido n-acetildiamino butirico.
UY36183A (es) Métodos para tratar infecciones
MX2016011308A (es) Agente para el control de endoparasitos.